Introduction {#S1}
============

The emergence of the SARS-CoV-2 novel coronavirus has led to a global pandemic (COVID-19), with more than 18 million cases as of August 2020([@R1]). While the global burden of disease has overwhelmed healthcare systems around the world, available data suggest that severe illness and death from COVID-19 are rare in the pediatric population([@R2]). One aspect of the COVID-19 pandemic that has eluded explanation is the striking diversity of clinical phenotypes accompanying SARS-CoV-2 infection, ranging from asymptomatic carriage to life threatening multi-organ failure([@R3]--[@R8]). Morbidity and mortality appear most severe among the elderly([@R9], [@R10]), while infection rates and hospitalizations among infants and children are substantially lower([@R1]). In a recently published study from China, 90% of children infected with SARS-CoV-2 exhibited mild symptoms or were asymptomatic([@R2]), and neonatal infections are limited to a handful of case reports. This led us to hypothesize that host factors determining SARS-CoV-2 cellular infectivity and viral attachment in the respiratory epithelium may be developmentally regulated. Differential expression of these viral attachment factors across lung development may provide biologic rationale for the variability in COVID-19 presentation.

Results and Discussion {#S2}
======================

To investigate how the expression of genes associated with SARS-CoV-2 susceptibility change during lung development, we analyzed a previously unpublished scRNA-seq dataset profiling the epithelial and stromal cells in the developing mouse lung at five timepoints ranging from embryonic day 18 (E18) to postnatal day 64 (P64) ([Fig. 1A](#F1){ref-type="fig"}--[B](#F1){ref-type="fig"}, [Fig. S1A](#SD1){ref-type="supplementary-material"}--[B](#SD1){ref-type="supplementary-material"}). We interrogated expression profiles of genes linked to SARS-CoV-2 infectivity by analyzing a total of 67,629 cells across these 5 timepoints ([Fig. 1C](#F1){ref-type="fig"}--[D](#F1){ref-type="fig"}). Previous work has suggested that SARSCoV-2 gains cellular entry by binding ACE2 on the cell surface([@R11]--[@R13]), then the spike-protein undergoes a protease-mediated cleavage facilitating fusion with the cell membrane ([@R14]). TMPRSS2 is the canonical protease mediating cellular entry for coronaviruses including SARSCoV-2([@R14]), although it should be noted that there are reports the SARS-CoV-2 spike protein may be cleaved by other proteases([@R13]). Consistent with recent reports analyzing single-cell transcriptomic data of the lung and other organs ([@R15]--[@R19]), we observed that during lung development, expression of *Ace2* was generally low, was largely restricted to epithelial cells, was most frequently and most highly expressed in secretory cells ([Fig. 1E](#F1){ref-type="fig"}), and was expressed in a small subset of alveolar type 2 (AT2) cells. In contrast, *Tmprss2* was expressed broadly in the epithelium and was most highly expressed in ciliated cells and alveolar type 1 (AT1) cells ([Fig. 1E](#F1){ref-type="fig"}). A small proportion of fibroblasts and pericytes expressed *Ace2*, but there was minimal *Ace2* or *Tmprss2* in endothelial or other stromal cells ([Fig. 1E](#F1){ref-type="fig"}). Examining the relative expression of *Tmprss2* and other putative priming proteases across developmental time (including furin and cathepsin B), we observed that specifically in ciliated airway epithelial cells, *Tmprss2* expression was significantly higher at P64 compared to all earlier developmental timepoints; a similar pattern was observed for *Ctsb*. In AT1 cells, *Tmprss2* expression generally increased during alveolarization into adulthood.

To provide tissue validation and to spatially and temporally localize expression of *Tmprss2*, we performed RNA-ISH using formalin fixed paraffin-embedded (FFPE) lung tissue from the same developmental time points used for scRNAseq, as well as lung tissue from 1yr and 2yr old mice. Colocalizing *Tmprss2* with *Scgb1a1* (secretory cells*), Foxj1* (ciliated cells), *Sftpc* (AT2 cells), and *Hopx* (AT1 cells) ([Fig. 2A](#F2){ref-type="fig"}), we observed an age-dependent progressive increase in the proportion of *Tmprss2+* cells among all cell types ([Fig. 2B](#F2){ref-type="fig"}). Further, in AT1 cells and ciliated cells, there was a marked increase in relative *Tmprss2* expression across developmental time that was most striking at 1 and 2 years of age ([Fig. 2B](#F2){ref-type="fig"}). *Tmprss2* exhibited relatively low expression in secretory cells although levels increased in adult and aged mice. AT2 cells showed even lower expression of *Tmprss2* when compared with other epithelial cells, with little detectable increase in expression across lung development . Notably, there was minimal detection of *Tmprss2* prenatally at E18, and relatively low levels in the saccular stage at P0 in all epithelial cell types. Combining RNA ISH with immunofluorescence for TMPRSS2 protein showed concordance between expression of the *Tmprss2* gene and the TMPRSS2 protein ([Fig. S2](#SD1){ref-type="supplementary-material"}), and the localization of TMPRSS2 protein expression in ciliated cells expressing *Foxj1*was confirmed ([Fig. S2](#SD1){ref-type="supplementary-material"}). Consistent with our transcriptomic data, basal *Ace2* expression detected by RNA-ISH was low with little change during development and aging ([Fig. S3](#SD1){ref-type="supplementary-material"}).

To determine whether *TMPRSS2* is also developmentally regulated in humans, we examined *TMPRSS2* expression by RNA-ISH across the human lifespan. We defined infants as individuals up to 2 years of age (n=7), children between the ages of 3 and 17 (n=9). Adult specimens were from subjects aged 54--69 (never smokers, n=4). Infants expressed *TMPRSS2* at very low levels across all four epithelial lineages evaluated, while children exhibited similarly low levels of *TMPRSS2* in secretory and alveolar epithelial cells with a significant increase in *FOXJ1+* ciliated cells ([Fig. 3A](#F3){ref-type="fig"}--[B](#F3){ref-type="fig"}). Adult subjects had higher *TMPRSS2* expression in secretory, ciliated, and AT1 cells relative to both pediatric groups with very little *TMPRSS2* expression in AT2 cells ([Fig. 3B](#F3){ref-type="fig"}). As with the murine experiments, combining RNA ISH with immunofluorescence for TMPRSS2 protein showed concordance between expression of the *Tmprss2* gene and the TMPRSS2 protein ([Fig. S3](#SD1){ref-type="supplementary-material"}). The localization of TMPRSS2 protein expression in ciliated cells expressing *Foxj1*, and the substantial increase of TMPRSS2 protein expression with aging was confirmed ([Fig. S4](#SD1){ref-type="supplementary-material"}). Human lung tissue demonstrated low levels of *ACE2* expression across in infants, children, and adult samples ([Fig S5](#SD1){ref-type="supplementary-material"}). These data are broadly consistent with results of a single-nucleus RNA-seq (snRNA-seq) study of infants, children and adults up to age 30 that was reported while this manuscript was being finalized, though notably that study only had 3 subjects per group and did not show tissue validation of their findings([@R20]).

To understand the relevance of our findings in the setting of COVID-19 infection, we analyzed autopsy specimens from the lungs of patients who died from complications of COVID-19 (n=3). Using RNA-ISH, we identified the presence of SARS-CoV-2 RNA in both the large airway and lung parenchyma. SARS-CoV-2 was localized to epithelial cells expressing *SCGB1A1* (secretory)*, FOXJ1* (ciliated), and *AGER* (AT1). Surprisingly, despite analyzing \> 150 *SFTPC* positive cells (corresponding to AT2), none contained detectable SARS-CoV-2 RNA by this assay ([Fig 4A](#F4){ref-type="fig"}--[B](#F4){ref-type="fig"}). In large airways (mainstem bronchus), SARS-CoV-2 co-localized with *TMPRSS2 in SCGB1A1+* secretory cells as well as *SCGB1A1-*negative (presumably ciliated) cells ([Fig. 4C](#F4){ref-type="fig"}), and SARS-CoV-2 RNA was highly colocalized in cells expressing *TMPRSS2* ([Fig. 4D](#F4){ref-type="fig"}). Since autopsy tissue likely represents end-stage disease, the surprising absence of SARS-CoV-2 in AT2 cells could be explained by changes in viral replication during the course of the illness and/or increased cytotoxicity of infected AT2 cells; alternatively direct viral infection of AT2 cells may not play as significant role in the disease pathophysiology as has been hypothesized. It is also possible that SARS-CoV-2 is localized to other cells in the lung that we did not look for, including inflammatory cells. These data do indicate that secretory, ciliated, and AT1 cells had the highest levels of *TMPRSS2* expression and that these cell types all harbored SARS-CoV-2 RNA in lung tissue from severely infected patients, similar to data observed in an *ex-vivo* infection model([@R21]). Immunofluorescence for TMPRSS2 protein showed localization of SARS-CoV-2 virus in cells expressing TMPRSS2. Together, these data suggest that priming protease TMPRSS2 expression may be a crucial determinant of SARS-CoV-2 infectivity in the lower respiratory tract.

The epithelial cell tropism of SARS-CoV-2 is dependent upon viral attachment and activation by cell-surface proteins, e.g. ACE2 and TMPRSS2. While ACE2 has been well studied in *in vitro* platforms of differentiated lung epithelium, our findings and prior studies ([@R15]--[@R17], [@R22]) suggest that ACE2 is expressed at low levels in respiratory epithelium ([Figures 1](#F1){ref-type="fig"}, [S3](#SD1){ref-type="supplementary-material"},[5](#SD1){ref-type="supplementary-material"}). Conversely, the rising expression of *TMPRSS2* with age in both the conducting airways and alveolar epithelium may explain the increased susceptibility to symptomatic infection and severe ARDS observed in adults relative to children. To date, there have been very few cases of vertical transmission of SARS-CoV-2 to newborns([@R23]), despite viral particles being identified in the placentas of women who were infected with SARS-CoV-2([@R24]). In light of the very low expression of *ACE2* in ciliated epithelial cells, our data indicate that ACE2-independent attachment may play a role in SARS-CoV-2 cellular entry and pathogenesis. CD147 (basigin, *BSG*) has also been proposed as an alternative SARS-CoV-2 receptor([@R25]) and is expressed broadly including in ciliated cells in which its expression increased across developmental time; in contrast, Bsg expression decreased in the other epithelial cell types ([Fig. S6A](#SD1){ref-type="supplementary-material"}--[B](#SD1){ref-type="supplementary-material"}). Alternatively, recent data indicate that ACE2 may be transiently induced by interferon signaling to facilitate cellular entry, with increased interferon signaling after initial viral entry propagating ACE2 expression in neighboring cells([@R26]). Across developmental time in the lung epithelium, we observed a progressively increasing interferon signature with increasing age, most prominent in AT2 and AT1 cells ([Fig. S7A](#SD1){ref-type="supplementary-material"}--[B](#SD1){ref-type="supplementary-material"}). This raises the possibility that the developing lung may have relatively less interferon "priming" and therefore have less efficient ACE2 induction to serve as the primary entry receptor to facilitate alveolar infectivity. In contrast, we did not observe developmental differences in basal expression of innate inflammatory genes linked to coronaviruses response including: *Irf3, Tnf, Mapk1/3, Nfkb1/2, and Cxcl15* ([@R26]--[@R29]) ([Fig. S7C](#SD1){ref-type="supplementary-material"}).

The very low levels of *TMPRSS2* expression in human infants, and nearly absent levels of expression of *Tmprss2* in prenatal mice, suggest a mechanism by which neonates may be relatively protected against severe forms of COVID-19. After the SARS outbreak in 2003, several groups([@R30]--[@R33]) reported that proteolytic cleavage of the SARS-CoV spike (S) protein is a prerequisite for viral activation and host cell entry, with SARS-CoV tropism for TMPRSS2-expressing cells in primates([@R34]). Prior work studying SARS-CoV has shown that inhibition of TMPRSS2 with the serine protease inhibitor Camostat, partially prevented SARS-CoV infection([@R35]), and addition of a cathepsin inhibitor (Aloxistatin) to Camostat potentiated the antiviral effect([@R35]).These data highlight the potential for TMPRSS2 inhibition as an effective strategy for reducing SARS-CoV-2 infection, although it is important to note this does not suggest TMPRSS2 is required for for SARS-CoV-2 entry *in vivo*.

In summary, these data suggest that developmental regulation of viral entry-factors may be the primary determinant of the age-related differences in SARS-CoV-2 susceptibility and severity. The identification of changes in *TMPRSS2* expression associated with age presents a biological rationale for the observed rarity of severe lower respiratory tract SARS-CoV-2 disease in children, and underscores the opportunity to consider *TMPRSS2* inhibition as a potential therapeutic target for SARS-CoV-2.

METHODS {#S3}
=======

Methods are described in detail in the [supplement](#SD1){ref-type="supplementary-material"}.

Data availability. {#S4}
------------------

Raw data and counts matrices used in generating this dataset are available through the Gene Expression Omnibus (GEO) (pending). Code used for dataset integration and analyses in this manuscript are available at <https://github.com/KropskiLab>.
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![Time-series scRNA-seq of the developing mouse lung.\
A) Overview of mouse lung developmental stages and timepoints sampled for scRNA-seq time-series. B) Workflow of scRNA-seq time series. Single cell suspensions were generated from at least 4 mice at each timepoint. Viable, Cd45-, Ter119- cells were selected and underwent scRNA-seq library preparation using the 10X Genomics Chromium 5' platform. c-d) UMAP embedding of 67,629 cells annotated by C) developmental timepoint and D) cell-type. E) Violin plot depicting expression of key SARS-CoV2 receptor *Ace2* and coreceptor *Tmprss2* across cell types in the jointly analyzed dataset. F) UMAP embedding of 4,369 epithelial cells after subsetting and reclustering. G,H) UMAP plots depicting relative expression of g) *Ace2* and h) *Tmprss2*. i) Relative expression of putative SARS-CoV-2 priming proteases across developmental time. \**p*\<3.125×10^−3^ by ANOVA across developmental timepoints.](nihpp-2020.05.22.111187-f0001){#F1}

![Spatial and temporal localization of *Tmprss2* expression across lung development.\
A) RNA in situ hybridization (ISH) of *Tmprss2* expression (white) with epithelial cell markers *Scgb1a1* (secretory cells, blue), *Foxj1* (ciliated cells, magenta), *Sftpc* (surfactant protein C, AT2 cells, green), *Hopx* (type 1 alveolar epithelial cells, red). Formalin fixed paraffin embedded tissue from lungs at timepoints E18, P0, P7, P14, P64, 12 months, and 24 months was used, with representative image data from timepoints P0, P7, P64, 12 months, and 24 months shown in the figure. Lungs from 3 mice at each time point were used, with ten 40X images obtained per slide. Scale bar = 100μm. B, C) Quantification of *Tmprss2* expression in each epithelial subtype across development measured as: B) a percentage of cellular area covered by *Tmprss2* probe for each cell expressing both *Tmprss2* and the epithelial cell marker; all data points are shown with mean +/− standard deviation (SD) and C) percentage of cells expressing the epithelial cell marker that also express *Tmprss2*, with positive *Tmprss2* expression defined has having 5 or more copies of *Tmprss2* probe; box and whisker plots are shown with mean and error bars reflecting minimum and maximum values for each timepoint. Greater than 1000 cells were counted at each timepoint. \*\*\*\**p*\<0.0001 by one-way ANOVA.](nihpp-2020.05.22.111187-f0002){#F2}

![Spatial and temporal localization of *TMPRSS2* expression in the lung across the human lifespan.\
A) RNA *in-situ* hybridization (ISH) of *TMPRSS2* expression (white) with epithelial cell markers *SCGB1A1* (secretory cells, blue), *FOXJ1* (ciliated cells, magenta), *SFTPC* (surfactant protein C, AT2 cells, green), *AGER* (AT1 cells, red). Formalin fixed paraffin embedded tissue from 20 human lungs between the ages of birth and 69 years was analyzed. We defined infants as birth-2 years, children 3years-17 years, and adult specimens were between 53--69 years of age. Ten 40X images were obtained per slide for analysis. Scale bar = 100 μm. B, C) Quantification of *TMPRSS2* expression in each epithelial subtype across development as measured as: B) a percentage of cellular area covered by *TMPRSS2* probe for each cell expressing both *TMPRSS2* and the epithelial cell marker and C) percentage of cells expressing the epithelial cell marker that also express *TMPRSS2*, with positive *TMPRSS2* expression defined has having 5 or more copies of *TMPRSS2* probe. Greater than 1000 cells were counted at each timepoint. \*\*\*\**p*\<0.0001, \*\**p*\<0.01 by one-way ANOVA.](nihpp-2020.05.22.111187-f0003){#F3}

![Spatial localization of SARS-CoV-2 RNA in lung autopsy tissue from fatal COVID-19.\
A) RNA-ISH of SARS-CoV-2 RNA (red) with epithelial cell markers *SCGB1A1 (*secretory cells, cyan), *FOXJ1* (ciliated cells, white), *SFTPC* (AT2 cells, green), *AGER* (AT1 cells, white); scale bar = 100μm. B) Quantification of cells containing SARS-CoV-2 RNA by epithelial subtype, as a percentage of total number of cells counted; a minimum of 150 cells were counted in each group. C)RNA ISH of large airway from same patient demonstrating RNA transcripts for *TMPRSS2* (white) in the same cells containing SARS-CoV-2 RNA (red), with secretory cells labeled in green (*SCGB1A1)* for context; scale bar = 100μm. D) Quantification of *TMPRSS2* expression in *SARS-CoV-2+* cells, more than 1000 cells were counted from the large airways of the 3 patients, *p\<0.05*. All percentages are shown in graphs with mean +/− standard deviation. E) RNA in situ hybridization (ISH) of *SARS-CoV-2* (red) with protein immunofluorescence for TMPRSS2 protein (white), scale bar = 100μm.](nihpp-2020.05.22.111187-f0004){#F4}
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